Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study. [PDF]
Wang S +11 more
europepmc +1 more source
Engineering immunity in osteosarcoma: nanomedicine strategies for overcoming immune evasion. [PDF]
Huang Q, Yu G, Shi B, Deng T.
europepmc +1 more source
Bond strength and interfacial stability of a universal adhesive to alendronate-treated dentin. [PDF]
Salem HS, Enan ET, Hamama H, Ismail MS.
europepmc +1 more source
The Bisphosphonate Accumulation Index (BAI): A Quantitative Metric for Cumulative Antiresorptive Exposure in Pre-Procedural Dental and Surgical Assessment. [PDF]
Zecca PA +5 more
europepmc +1 more source
Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis. [PDF]
Flanigan J +8 more
europepmc +1 more source
A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review. [PDF]
Mann RS +6 more
europepmc +1 more source
The emerging role of subchondral bone homeostasis in osteoarthritis. [PDF]
Donat A +5 more
europepmc +1 more source
Bone Mineral Density After Transitioning From Denosumab to Alendronate [PDF]
Context: There are few studies on patients transitioning from denosumab to bisphosphonates. Objective: To investigate patient characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate.
David Kendler +2 more
exaly +4 more sources
Related searches:
Alendronate was synthesized in 1970s in a search for inhibitors of calcification. Istituto Gentili investigators identified it as a potent inhibitor of bone resorption and obtained a patent covering its use in the treatment of osteoporosis and other disorders of excessive bone resorption in the 1980s.
Steven R. Cummings +3 more
openaire +2 more sources

